Envista Holdings Corp
HealthcareNYSE:NVST · New York Stock Exchange
+$0.10 today
Vol 2.17M · Avg 2.97M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $47.0M +104.2% | -$1.1B -1016.4% | -$100.2M -141.2% | $243.1M -28.6% | $340.5M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $116.0M -24.9% | $154.5M -5.0% | $162.6M +0.3% | $162.1M +6.7% | $151.9M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $11.4M +139.3% | -$29.0M +21.6% | -$37.0M | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $0 -100.0% | $35.3M +15.0% | $30.7M +0.7% | $30.5M +8.2% | $28.2M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $8.9M -90.9% | $97.4M +189.9% | -$108.4M +60.1% | -$271.7M -33.7% | -$203.2M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$48.5M -585.0% | $10.0M +158.8% | -$17.0M +76.1% | -$71.0M -64.4% | -$43.2M | $592.6M | $1.3B | $626.2M |
| Inventory | -$29.1M -908.3% | $3.6M -89.7% | $35.1M +188.0% | -$39.9M +39.5% | -$66.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $7.5M +725.0% | -$1.2M +97.4% | -$46.3M -204.0% | $44.5M +319.2% | -$20.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $79.0M -7.1% | $85.0M +206.0% | -$80.2M +60.9% | -$205.3M -178.6% | -$73.7M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $92.4M -92.3% | $1.2B +264.9% | $328.0M +1654.0% | $18.7M -57.7% | $44.2M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $275.7M -18.1% | $336.5M +22.1% | $275.7M +50.9% | $182.7M -49.5% | $361.6M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$45.3M -34.0% | -$33.8M +41.9% | -$58.2M +23.1% | -$75.7M -38.4% | -$54.7M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 +100.0% | -$622.3M -300.5% | $310.4M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$9.9M +69.8% | -$32.8M | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $10.4M +7.2% | $9.7M -9.3% | $10.7M -80.9% | $56.0M +391.2% | $11.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$6.3M -373.9% | $2.3M +115.4% | -$14.9M +2.6% | -$15.3M -247.7% | -$4.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$51.1M +6.4% | -$54.6M +12.5% | -$62.4M +90.5% | -$657.3M -350.2% | $262.7M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$900.0K +99.1% | -$100.0M -186.7% | $115.4M +57800.0% | -$200.0K +100.0% | -$475.7M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.8M +16.7% | $2.4M -78.8% | $11.3M -48.2% | $21.8M +11.8% | $19.5M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$166.6M | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$6.2M -1.6% | -$6.1M +21.8% | -$7.8M +14.3% | -$9.1M +3.2% | -$9.4M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$170.9M -64.8% | -$103.7M -187.2% | $118.9M +851.2% | $12.5M +102.7% | -$465.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $88.9M +281.1% | -$49.1M -5555.6% | $900.0K +119.6% | -$4.6M -117.7% | $26.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $142.6M +10.5% | $129.1M -61.2% | $333.1M +171.4% | -$466.7M -352.7% | $184.7M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $230.4M -23.9% | $302.7M +39.2% | $217.5M +103.3% | $107.0M -65.1% | $306.9M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
Alignment Healthcare, Inc.
NASDAQ:ALHC
$4.08B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.60B
ICU Medical, Inc.
NASDAQ:ICUI
$3.55B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.01B
Privia Health Group, Inc.
NASDAQ:PRVA
$2.95B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
GRAIL, Inc.
NASDAQ:GRAL
$2.57B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.02B
SEC Filings
Recent regulatory filings
No filings found.
Does NVST generate free cash flow?
Envista Holdings Corp (NVST) generated $230.40M of free cash flow in fiscal 2025.
How much operating cash flow does NVST produce?
Operating cash flow was $275.70M, before capital expenditures of $45.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.